You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
為應對抗擊新冠病毒緊急需求 中國醫療集團(08225.HK)邁可欣即將開展海外臨牀研究
格隆匯 04-24 07:10

格隆匯4月24日丨中國醫療集團(08225.HK)公佈,為迴應國際抗擊新冠病毒COVID-19戰役市場緊急需求,公司與一家國際CRO公司Pharmadesk簽署了《邁可欣口服液生物等效性研究協議》,Pharmadesk公司已經成功地為全球客户進行了500多項符合國際規範市場法規要求的BE研究,沒有一項研究被EMEA或美國FDA拒絕。

邁可欣(利托那韋(Ritonavir)口服液)是公司關聯企業萬全萬特製藥(廈門)有限公司於2020年2月獲得獨家復產批准的產品,利托那韋(Ritonavir)是抗病毒蛋白酶抑制劑,洛匹那韋/利托那韋為國家衞健委針對新型肺炎的國家版診療方案推薦用藥。公司旗下新型冠狀病毒肺炎臨牀特別專案研究組、中國科學院武漢病毒研究所等也發現邁可欣對新型冠狀病毒(COVID-19)有抑制作用。

新冠肺炎病毒將與公司長期共存。集團正與北京大學、廈門大學和海南大學的科學家共建世界級抗病毒藥物的研究院。集團通過“研究型治療RWS-Therapy模式”展開對COVID-19的後臨牀研究和治療,與微醫集團和妙手醫生集團聯手百名心理醫療專家和控煙專家,展開疫情後時代的精神心理健康的雲端喜心診所和護肺悦戒煙診所馳援。管理層相信這將會增強公司在臨牀研究領域的競爭力,在戰勝病毒、治癒患者的過程中為股東創造更大回報。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account